Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.
Over 700 patients with HIV-associated wasting while receiving HAART were randomly assigned to double-blind treatment for 12 weeks with recombinant human growth hormone (rhGH) daily or on alternate days, or to placebo. Maximum exercise intensity increased by a median of 2.35kJ in the alternate-days group and 2.60 kJ in the daily group but decreased by 0.25kJ in the placebo group. The median difference between the daily and placebo groups was 2.85 kJ (P < .0001). These improvements suggest that rhGH treatment may enable patients with wasting to perform activities of daily living that would be exhausting without rhGH treatment.
Evans
William J
WJ
Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Kotler
Donald P
DP
Staszewski
Schlomo
S
Griffin
George E
GE
Isgaard
Jorgen
J
Gertner
Joseph M
JM
O'Brien
Fanny
F
Svanberg
Elisabeth
E
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D001823:Body Composition / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D019247:HIV Wasting Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D019382:Human Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011336:Probability; D011994:Recombinant Proteins / Q000008:administration & dosage; D012016:Reference Values; D018570:Risk Assessment; D016896:Treatment Outcome
D011994:Recombinant Proteins; D019382:Human Growth Hormone